Presence of dendritic cells in malignant pleural effusion: pilot study
Agata Surdacka1, Paweł Krawczyk, Małgorzata Dańko
1Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland.
Insights
This study examined myeloid (DC1) and lymphoid (DC2) dendritic cells in lung cancer patients. Interferon alpha (IFN-alpha) treatment may increase DC2 activity, potentially causing unfavorable immunotolerance.
Area of Science:
- Immunology
- Oncology
Background:
- Malignant pleural effusion is associated with lung cancer.
- Dendritic cells (DCs) play a crucial role in immune responses.
- Understanding DC subsets in cancer is vital for treatment strategies.
Purpose of the Study:
- To quantify myeloid (DC1) and lymphoid (DC2) dendritic cells in lung cancer patients' pleural effusion and blood.
- To assess the impact of intrapleural interferon alpha (IFN-alpha) treatment on these DC subsets.
Main Methods:
- Flow cytometry was used to phenotype mononuclear cells.
- Monoclonal antibodies (anti-BDCA-1 FITC, anti-BDCA-2 FITC) were utilized.
- Analysis was performed on samples from lung cancer patients, including those treated with IFN-alpha (Roferon A).
Main Results:
- Patients not treated with IFN-alpha showed low DC2 percentages and a high BDCA-1/BDCA-2 ratio in pleural effusion.
- This suggests an intensive Th1 response contributing to inflammation and effusion.
- IFN-alpha therapy was associated with increased DC2 activity.
Conclusions:
- IFN-alpha therapy might induce unfavorable immunotolerance in lung cancer patients.
- Increased DC2 activity is a potential mechanism for this immunotolerance.
- Further research is needed to elucidate the complex immune effects of IFN-alpha in lung cancer.
Abstract:
The objective of the study was to evaluate the number of myeloid (DC1) and lymphoid (DC2) dendritic cells in malignant pleural effusion and peripheral blood of patients with lung cancer as well as to estimate changes in their presence during intrapleural interferon alpha treatment. The study comprised eight subjects including two patients treated with Roferon A. Isolated mononuclear cells were phenotyped with the following monoclonal antibodies: anti-BDCA-1 FITC and anti-BDCA-2 FITC, and analyzed using FACSCalibur flow cytometry. Very low percentage of DC2 and high BDCA-1/BDCA-2 ratio in malignant pleural effusion of patients not treated with IFN-alpha suggest intensive Th1 response probably responsible for inflammatory state maintenance and effusion constant development. The results of our study indicate that apart from the suggested antitumour activity, IFN-alpha therapy may result in unfavourable immunotolerance caused by increased DC2 activity.
